Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.
Angiogenesis Inhibitors
/ administration & dosage
Bevacizumab
/ administration & dosage
Female
Follow-Up Studies
Gestational Age
Humans
Infant, Newborn
Intravitreal Injections
Laser Coagulation
/ methods
Male
Receptors, Vascular Endothelial Growth Factor
/ antagonists & inhibitors
Retina
/ pathology
Retinopathy of Prematurity
/ diagnosis
Retrospective Studies
Time Factors
Tomography, Optical Coherence
/ methods
Treatment Outcome
Journal
Ophthalmic surgery, lasers & imaging retina
ISSN: 2325-8179
Titre abrégé: Ophthalmic Surg Lasers Imaging Retina
Pays: United States
ID NLM: 101599215
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
29
09
2019
accepted:
26
12
2019
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
15
4
2021
Statut:
ppublish
Résumé
To compare morphologic and functional status at age 4 years for patients treated in one eye with laser photocoagulation and the other eye with intravitreal bevacizumab (IVB) injection for Type 1 retinopathy of prematurity (ROP). In this single-center, randomized, controlled trial, best-corrected visual acuity (BCVA) in logMAR was obtained along with spherical equivalent refraction (SER), fluorescein angiography (FA), optical coherent tomography (OCT), and OCT angiography (OCTA). Eighteen babies (36 eyes) were selected for this study. BCVA and SER were similar in the two groups, but six patients had anisometropia of 4 diopters or more. IVB-treated eyes tended to have thinner foveal thickness than laser-treated eyes (mean difference: -5.33 pixels; 95% confidence interval, -9.62 to -1.05). Although the differences found here are minimal between the IVB-treated and laser-treated groups, further long-term evaluation of not only FA, but also OCT and OCTA, are needed in larger studies. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:180-186.].
Sections du résumé
BACKGROUND AND OBJECTIVE
To compare morphologic and functional status at age 4 years for patients treated in one eye with laser photocoagulation and the other eye with intravitreal bevacizumab (IVB) injection for Type 1 retinopathy of prematurity (ROP).
PATIENTS AND METHODS
In this single-center, randomized, controlled trial, best-corrected visual acuity (BCVA) in logMAR was obtained along with spherical equivalent refraction (SER), fluorescein angiography (FA), optical coherent tomography (OCT), and OCT angiography (OCTA).
RESULTS
Eighteen babies (36 eyes) were selected for this study. BCVA and SER were similar in the two groups, but six patients had anisometropia of 4 diopters or more. IVB-treated eyes tended to have thinner foveal thickness than laser-treated eyes (mean difference: -5.33 pixels; 95% confidence interval, -9.62 to -1.05).
CONCLUSION
Although the differences found here are minimal between the IVB-treated and laser-treated groups, further long-term evaluation of not only FA, but also OCT and OCTA, are needed in larger studies. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:180-186.].
Identifiants
pubmed: 32211908
doi: 10.3928/23258160-20200228-07
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-186Informations de copyright
Copyright 2020, SLACK Incorporated.